Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Receivables - Other: 2020-2023

Historic Receivables - Other for Cartesian Therapeutics (RNAC) over the last 3 years, with Dec 2023 value amounting to $3.0 million.

  • Cartesian Therapeutics' Receivables - Other fell 47.73% to $980,000 in Q3 2024 from the same period last year, while for Sep 2024 it was $980,000, marking a year-over-year decrease of 47.73%. This contributed to the annual value of $3.0 million for FY2023, which is 5.72% down from last year.
  • Cartesian Therapeutics' Receivables - Other amounted to $3.0 million in FY2023, which was down 5.72% from $3.2 million recorded in FY2022.
  • Cartesian Therapeutics' 5-year Receivables - Other high stood at $3.2 million for FY2022, and its period low was $1.4 million during FY2020.
  • Moreover, its 2-year median value for Receivables - Other was $3.1 million (2022), whereas its average is $3.1 million.
  • Data for Cartesian Therapeutics' Receivables - Other shows a maximum YoY fell of 5.72% (in 2023) over the last 5 years.
  • Cartesian Therapeutics' Receivables - Other (Yearly) stood at $1.4 million in 2020, then reached $3.2 million in 2022, then declined by 5.72% to $3.0 million in 2023.